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Abstract
Background: Tuberculosis (TB) is a major public health problem in Nepal. Strain variation in Mycobacterium tuberculosis may
influence the outcome of TB infection and disease. To date, the phylogenetic diversity of M. tuberculosis in Nepal is
unknown.
Methods and Findings: We analyzed 261 M. tuberculosis isolates recovered from pulmonary TB patients recruited between
August 2009 and August 2010 in Nepal. M. tuberculosis lineages were determined by single nucleotide polymorphisms (SNP)
typing and spoligotyping. Drug resistance was determined by sequencing the hot spot regions of the relevant target genes.
Overall, 164 (62.8%) TB patients were new, and 97 (37.2%) were previously treated. Any drug resistance was detected in 50
(19.2%) isolates, and 16 (6.1%) were multidrug-resistant. The most frequent M. tuberculosis lineage was Lineage 3 (CAS/
Delhi) with 106 isolates (40.6%), followed by Lineage 2 (East-Asian lineage, includes Beijing genotype) with 84 isolates
(32.2%), Lineage 4 (Euro-American lineage) with 41 (15.7%) isolates, and Lineage 1 (Indo-Oceanic lineage) with 30 isolates
(11.5%). Based on spoligotyping, we found 45 different spoligotyping patterns that were previously described. The Beijing
(83 isolates, 31.8%) and CAS spoligotype (52, 19.9%) were the dominant spoligotypes. A total of 36 (13.8%) isolates could
not be assigned to any known spoligotyping pattern. Lineage 2 was associated with female sex (adjusted odds ratio [aOR]
2.58, 95% confidence interval [95% CI] 1.42–4.67, p = 0.002), and any drug resistance (aOR 2.79; 95% CI 1.43–5.45; p = 0.002).
We found no evidence for an association of Lineage 2 with age or BCG vaccination status.
Conclusions: We found a large genetic diversity of M. tuberculosis in Nepal with representation of all four major lineages.
Lineages 3 and 2 were dominating. Lineage 2 was associated with clinical characteristics. This study fills an important gap on
the map of the M. tuberculosis genetic diversity in the Asian region.
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Introduction
Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a
global health threat with an estimated nine million incident cases
and 440,000 multidrug-resistant TB cases worldwide [1]. The
incidence of TB was 163 per 100,000 population in 2010, and
multidrug resistance (MDR) occurred in 2.9% of new cases and
11.7% of previously treated cases based on the most recent drug
resistance survey in 2006 [2,3]. In Nepal, the National Tubercu-
losis Control Programme adopted Directly Observed Short
Course therapy (DOTS) in 1995.
Mycobacterium tuberculosis complex (MTBC) has a global phylo-
geographic population structure consisting of six main phyloge-
netic lineages [4–6]: Lineage 1 (also known as Indo-Oceanic
Lineage), Lineage 2 (East-Asian Lineage, includes the Beijing
genotype), Lineage 3 (Delhi/CAS), Lineage 4 (Euro-American
Lineage), and Lineages 5 and 6 (M. africanum West African lineages
1 and 2). These lineages are associated with specific geographic
regions and human populations [4,7–9]. Lineage 2, for example, is
most often isolated in countries in Asia and the former Soviet
Union [10]. There is increasing evidence that in addition to host
and environmental factors, the epidemiology of TB may also be
influenced by bacterial strain variation [11–19]. For example,
Lineage 2 (includes the Beijing genotype) has been repeatedly
associated with drug resistance in a wide range of settings and
countries [20–23], while a few studies could not find evidence for
such an association [24–26].
There are several genotyping techniques to define the genetic
diversity of M. tuberculosis [7,27,28]. Spoligotyping is a widely used
genotyping technique [29,30]. It is based on the repetitive DNA
region known as the Direct Repeat (DR) locus in M. tuberculosis
[28]. This region is characterized by series of direct repeats
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interspersed by short unique regions called ‘‘spacers’’. However,
these spacers exhibit a high rate of change, and convergent
evolution can lead to identical genetic character states in
phylogenetically unrelated strains [5,31]. By contrast, genomic
deletions and single nucleotide polymorphism (SNPs) evolve more
slowly. Recent advances in comparative genomics have led to the
development of more robust markers to study the genetic diversity
[7,32–36], and are therefore ideal for determining phylogenetic
lineages and sub-lineages [11].
Nepal lies between two high TB burden countries, India and
China which together account for one third of the world’s TB
cases [37]. To date, there are no data on the phylogenetic diversity
of M. tuberculosis in Nepal. The aims of the study were to describe
the main M. tuberculosis lineages and spoligotypes circulating in
Nepal, and to explore possible associations with clinical and
epidemiological characteristics.
Methods
Ethics Statement
This study was approved by the Nepal Health Research
Council, Nepal and the Ethics Committee of the Canton of Basel
(EKBB), Switzerland. All study participants provided written
informed consent. After diagnosis, the TB cases were referred to
DOTS centers for treatment as provided by the Nepal Govern-
ment’s National TB Control Program.
Study Setting
The study was based on a convenience sample of TB patients
mainly representing populations from Kathmandu and the
surrounding area. TB suspects who reported symptoms of TB
including cough for more than two weeks, chest pain, night sweat
and fever were recruited at the German Nepal Tuberculosis
Project (GENETUP), Kathmandu, Nepal. Patients already
undergoing DOTS therapy were also enrolled, if found smear-
positive during follow-up visits. GENETUP is a national reference
laboratory, technically and financially supported by ‘‘Kuratorium
Tuberkulose in der Welt e. V.’’ (Gauting, Germany), and is the
main referral center for culture and drug susceptibility testing to
diagnose MDR and extensively drug-resistant TB.
Study Population and Data Collection
We included a total of 261 culture-confirmed TB cases
diagnosed between August 2009 and August 2010. We collected
socio-demographic and clinical data including previous TB
episodes, treatment history, HIV, and BCG vaccination status.
The information was collected by physicians and trained medical
and nursing staff. A new case of TB was defined as a patient who
had not taken anti-TB drugs for at least one month according to
WHO guidelines [38]. A previously treated case was defined as a
patient who received TB treatment for one month or more. BCG
vaccination status was defined based on the presence or absence of
a BCG scar.
Culture, DNA Extraction and Identification of
M. tuberculosis Complex
Sputum samples were cultured on Lo¨wenstein Jensen (LJ)
growth medium following standard microbiological laboratory
procedures. The DNA was extracted by re-suspension of MTBC
colonies in 500 ml of sterile distilled water, heat killed at 90uC for
one hour, and centrifuged. The supernatants were preserved at
4uC until further use. MTBC strains were identified by multiplex
polymerase chain reaction (PCR) by targeting the rpoB gene
region. We used the forward primers K-0155 (59-TCCTCGAT-
GACGCCGCTTTCT-39) and K-0209 (59-AYATCGAC-
CACTTCGGYAACC-39), and the reverse primer K-0156 (59-
TCRGAGATCTTGCGCTTCTGS-39). PCR conditions were as
follows: initial denaturation step for 5 minutes at 96uC, 35
amplification cycles of 96uC for 40 secs (denaturation), 62uC for
30 secs (annealing), 72uC for 1 min (extension), and a final
extension cycle of 7 minutes at 72uC. The amplicons were
separated by electrophoresis on a 2% agarose gel. The PCR
yielded a 849 bp amplicon in M. tuberculosis isolates, compared to a
1539 bp amplicon in non-tuberculous mycobacteria. All M.
tuberculosis isolates were stored in glycerol medium at –70o C.
Determination of the Main M. tuberculosis Lineages
We determined the main phylogenetic lineages of M. tuberculosis
by real-time PCR using fluorescence-labeled probes (Taqman,
Applied Biosystems, USA) targeting lineage-specific SNPs as
previously described [4,32,36].
Spoligotyping
Spoligotyping was performed according to the manufacturer’s
instructions, using commercially available kits from Isogen
Bioscience BV (Maarssen, The Netherlands) [30,39]. Spoligotyp-
ing patterns were defined according to the definitions in the
SITVITWEB database (http://www.pasteur-guadeloupe.fr:8081/
SITVIT_ONLINE/) accessed on October 22, 2012. The
SITVITWEB global database has documented 7,105 spoligotyp-
ing patterns from a global collection of 53,816 strains [40]. All
patterns that could not be assigned were considered orphan
spoligotypes.
Molecular Drug Resistance Testing
As phenotypic drug susceptibility testing results were not
available for all strains, we used molecular methods to detect
drug resistance in our study. Molecular drug resistance testing
was performed on all strains by direct sequencing of the hotspot
regions of the target genes for rifampicin (rpoB), isoniazid (inhA
promoter region and katG), and streptomycin (rpsL). MDR
strains were then further sequenced and analyzed for etham-
butol (embB), fluoroquinolones (gyrA) and aminoglycoside (rrs)
resistance by sequencing of the relevant gene segments. For the
rpoB region, we used an in-house PCR assay with primer pair
K-0155 and K-0209 as described above. For all other target
genes, PCR primers and PCR conditions were adapted from
previously published studies [41–43].The sequences were
analyzed with M. tuberculosis H37Rv as reference sequence
using the Staden software package [44,45], and compared to
the publicly available web-based database (http://www.
tbdreamdb.com/) [46]. Any drug resistance was defined as
resistance to isoniazid, rifampicin, streptomycin, ethambutol,
fluoroquinolones, and/or aminoglycosides. MDR was defined as
resistance to at least isoniazid and rifampicin.
Statistical Analyses
We used Chi-square test to test the statistical significance of
differences between groups in binary variables, and the Kruskal
Wallis rank test for continuous variables. Logistic regression
models were used to compare patient characteristics associated
with Lineage 2 (includes the Beijing genotype) compared to all
other lineages (Lineages 1, 3 and 4), adjusted for age, sex,
treatment history, BCG vaccination status, and any drug
resistance. All statistical analyses were performed in STATA
10.1 (Stata Corp., College Station, TX, USA).
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Table 1. Description of the main Mycobacterium tuberculosis lineages and spoligotyping patterns from Nepal (total number of
isolates analyzed: n = 261).
Lineage
Spoligotyping
family Spoligotyping pattern (spacers 1–43) SIT n %
1 EAI5 &&&&&&&&&&&&&&&&&&&&&&&&&&&&%%%%&%&&&&&%%%% 138 10 33.33
1 EAI3_IND &%%&&&&&&&&&&&&&&&&&&&&&&&&&%%%%&%&&%%%&&&& 11 4 13.33
1 EAI1_SOM %%%&&&&&&&&&&&%&&&&&&&&&&&&&%%%%&%&&&&&%&&& 1734 1 3.33
1 EAI1_SOM &&&&&&&&&&&&&&&&&&&&&&&&&&&&%%%%&%&&&&&%&&& 48 1 3.33
1 EAI2_MANILLA &&%&&&&&&&&&&&&&&&&%%&&&&&&&%%%%&%&&&&&&&&& 19 1 3.33
1 EAI6_BGD1 &&&&&&&&&&&&&&&&&&&&&&%&&&&&%%%%&%&&%&&&&&& 292 1 3.33
1 Orphan &&&&&&&&&&&&&&&&&&&&&&&&&&%%%%%%&%&&&&&%%%% - 1 3.33
1 Orphan %%%&&&&&&&&&&%&&&&&&&&&&&&&&%%%%&%&&%%%&&&& - 1 3.33
1 Orphan &&&&&&&&&&&&&&&&&&&&&&&&&&%&%%%%&%&&&&&%&&& - 1 3.33
1 Orphan &&&&&&&&&%&&&&&&&&&&&&&&&&&&%%%%&%&&&&%%%%% - 1 3.33
1 Orphan &&&&&&&&&&&&&&&&&&&&&&&&&&&&%%%%&%%%&&&%%%% - 1 3.33
1 Orphan &&&&&&&&&&&%&&&&&&&&&&&&&&&&%%%%&%&&&&&%%%% - 1 3.33
1 Orphan &&&&&&&&&&&&&%%%&&&&&&&&&&&&%%%%&%&&&&&%%%% - 1 3.33
1 Orphan &&&&&&&&&&&&&&&&&&&&&&%&%%%&%%%%%%&&%&&&&&& - 1 3.33
1 Orphan &&&&&&&&&&&&&%%%%&%%%%%%%&%%%%%%%%&&%&&&&&& - 1 3.33
1 Orphan &&&&&&&&&&&&&&%%%%&&&&&&&&&&%%%%&%&&&&&%%%% - 1 3.33
1 Orphan &%%&&&&&&&&&&%&&&&&&&&&&&&&&%%%%&%&&%%%&&&& - 1 3.33
1 Orphan &%%&&&&%%%%%%%%%%%&&&&&&&&&&%%%%&%&&%%%&&&& - 1 3.33
Subtotal 30 100.00
2 Beijing %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%&&&&&&&&& 1 82 97.62
2 Beijing %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%&&&&&&%&& 941 1 1.19
2 Beijing-like %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%&&&&&& 250 1 1.19
Subtotal 84 100.00
3 CAS1_DELHI &&&%%%%&&&&&&&&&&&&&&&%%%%%%%%%%%%&&&&&&&&& 26 52 49.06
3 CAS &&&%%%%&&&&&&&&&&&&%%%%%%%%%%%%%%%%%&&&&&&& 599 9 8.49
3 CAS &&&%%%%&&&&&&&&&&&&&&&%%%%%%%%%%%%%%&&&&&&& 357 6 5.66
3 CAS2 &&&%%%%%%%&&&&&&&&&&&&%%%%%%%%%%%%&&&&&&&&& 288 3 2.83
3 CAS1_DELHI &&&%%%%&&&&&&&&&&&&&&&%%%%%%%%%%%%&&%&&&&&& 428 3 2.83
3 CAS1_DELHI &&&%%%%&&&&&&&&&&&&&&&%%%%%%%%%%%%&%&&&&&&& 1091 3 2.83
3 CAS1_DELHI &&&%%%%&&&&&&&&&&&&&&&%%%%%%%%%%%%&&%%%%%&& 2147 2 0.94
3 CAS1_DELHI &&&%%%%&&&&&&&&&&&&&&&%%%%%%%%%%%%&&%%&&&&& 25 1 0.94
3 U (CAS_ANCESTOR) &&&%%%%&&&&&&&&&&&&&&&%%&&&&&&&&&%%%%&&&&&& 27 1 0.94
3 CAS1_DELHI &&&%%%%&&&&&&&%&&&&&&&%%%%%%%%%%%%&&&&&&&&& 141 1 0.94
3 CAS &&&%%%%&&&&&&&&&&&&&&%%%%%%%%%%%%%&&&&&&&&& 142 1 0.94
3 CAS &&&%%%%&&&&&&&&&&&&&&&%%%%%%%%%%%%%&&&&&&&& 203 1 0.94
3 CAS1_DELHI &&&%%%%&&&&&&&&&&&&&&&%%%%%%%%%%%%&&%%%&&&& 381 1 0.94
3 CAS1_DELHI &&&%%%%&&&&&&&&&&&&&&&%%%%%%%%%%%%&&&&&%&&& 429 1 0.94
3 CAS &&&%%%%&&&&&&&&&&&&&%%%%%%%%%%%%%%&&&&&&&&& 1093 1 0.94
3 CAS &&&%%%%&&&&&&&&&&&%%%%%%%%%%%%%%%%%%&&&&&&& 1422 1 0.94
3 CAS &&&%%%%%&&&&&&&&&&&&&&%%%%%%%%%%%%&&&&&&&&& 1551 1 0.94
3 CAS1_DELHI &&&%%%%&&&&&&&&&&&%&&&%%%%%%%%%%%%&&&&&&&&& 1590 1 0.94
3 CAS1_DELHI &&&%%%%&&&&&&&&&&&&&&&%%%%%%%%%%%%%%%%&&&&& 1789 1 0.94
3 Beijing 1 %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%&&&&&&&&& 1 1 0.94
3 Orphan &&&%%%%&&&&&&&&&%&&&&&%%%%%%%%%%%%%%%%&&&&& - 3 0.94
3 Orphan &&&%%%%&&&&&&&&&%%%%%%%%%%%%%%%%%%%%%%%&&&& - 1 0.94
3 Orphan &&&%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%&&&&&%&&& - 1 0.94
3 Orphan &&&%%%%&&&&&&%%&&&&&&&%%%%%%%%%%%%&&&&&&&&& - 1 0.94
3 Orphan &&&%%%%&&&&&&&&&&&&%%%%%%%&%%%%%%%%%&&&&&&& - 1 0.94
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Results
Patient Characteristics
Of the 261 patients included in this study, 164 (62.8%) were
new TB cases. Overall, 182 (69.73%) were male, and the median
age was 31 years (interquartile range [IQR] 23–50). Females were
significantly younger than males (median age 26 versus 35 years,
p,0.001). HIV status was known in 26 patients; of these 8 (30.8%)
were HIV-positive. Most patients originated from Kathmandu
valley (153 cases, 58.6%), followed by 104 cases (39.8%) from
different districts of Nepal, and four patients (1.5%) who were born
in India.
Mycobacterium tuberculosis Genotyping and Lineage
Assignment
We analyzed a total of 261 M. tuberculosis isolates (one from
each patient). The SNP-typing results showed the presence of
four different M. tuberculosis lineages (Table 1). The most
Table 1. Cont.
Lineage
Spoligotyping
family Spoligotyping pattern (spacers 1–43) SIT n %
3 Orphan &&&%%%%&&&&&&&&&%&&&&&%%%%%%%%%%%%&&&%&&&&& - 1 0.94
3 Orphan &&&%%%%&&&&&&&&&&&&&&&%&&&&&&&&&&%%%&&&&&&& - 1 1.89
3 Orphan &&%%%%%&&&&&&&&&&&&&&&%%%%%%%%%%%%&&%%&&&&& - 1 0.94
3 Orphan &&&%%%%&&&&&&&&%%%%%%%%%%%%%%%%%%%%%%%%%&&& - 1 0.94
3 Orphan &&&%%%%&&&&&&&&&%&&&&&%%%%%%%%%%%%&&&%%%%%& - 1 0.94
3 Orphan &&&%%%%%%%&&&&&&&&&&&&%%%%%%%%%%%%%%%%%%%%% - 1 0.94
3 Orphan &&&%%%%&&&&&&&&&&&&&&%%%%%%%%%%%%%%%%%%%%%% - 1 2.83
3 Orphan &&&%%%%&&&&&&&&%%%%%%%%%%%%%%%%%%%%%%%%%&&& - 1 0.94
Subtotal 106 100.00
4 H3 &%%&&&&&&&&&&&&&&&&&&&&&&&&&&&%&%%%%&&&&&&& 655 6 14.63
4 T2 &&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%%%%&&&&&&& 52 2 4.88
4 T3 &&&&&&&&&&&&%&&&&&&&&&&&&&&&&&&&%%%%&&&&&&& 37 3 7.32
4 S &&&&&&&&%%&&&&&&&&&&&&&&&&&&&&&&%%%%&&&&&&& 34 2 4.88
4 T1 &&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%%%%&&&&&&& 53 4 9.76
4 X2 &&&&&&&&&&&&&&&&&%&&&&&&&&&&&&&&%%%%&&%%%%& 137 2 4.88
4 T1 &&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%%%%&&%%%%& 244 2 4.88
4 H1 &&&&&&&&&&&&&&&&&&&&&&%%&%%%%%%&%%%%&&&&&&& 620 2 4.88
4 LAM9 &&&&&&&&&&&&&&&&&&&&%%%%&&&&&&&&%%%%&&&&&&& 42 1 2.44
4 H3 &&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%&%%%%&&&&&&& 50 1 2.44
4 T2–T3 &&&&&&&&&&&&%&&&&&&&&&&&&&&&&&&&%%%%&&&%&&& 73 1 2.44
4 T1 &&&&%&&&&&&&&&&&&&&&&&&&&&&&&&&&%%%%&&&&&&& 154 1 2.44
4 T1 &&&&&&&&&&&&%%%%&&&&&&&&&&&&&&&&%%%%&&&&&&& 102 1 2.44
4 X1 &&&&&&&&&&&&&&&&&%&&&&&&&&&&&&&&%%%%&&&&&&& 119 1 2.44
4 H1 &&&&&&&&&&&&&&&&&&&&&%%%&%%%%%%&%%%%&&&&&&& 283 1 2.44
4 T1 &&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%%%%&&&&&%% 628 1 2.44
4 H3 &&&&&&&&&&&&%&&&&&&&&&&&&&&&&%%&%%%%&&&&&&& 929 1 2.44
4 Orphan &&&&&&&&&&&&&&&&&&&&%&%%%%&&&&&&%%%%&&&&&&& - 1 2.44
4 Orphan %&&&&&%&&&&&&&&&&%&&&&&&&&&&&&&&%%%%&&&&&&& - 1 2.44
4 Orphan &&&&&&%&&%&&&&&&&&%&&&&&&&&&&&&&%%%%%&&&&&& - 1 2.44
4 Orphan &%&&&&&&&&&&&&%%&&&&&&&&&&&&&&&&%%%%&&&&&&& - 1 2.44
4 Orphan &%&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&%%%%%&&&&&& - 1 2.44
4 Orphan &&&%&&&&%%&&%&&&&&&&&&&&&&&&&&&&%%%%&&&&%&& - 1 2.44
4 Orphan &&&&&&&&&&&&&&&&&&&&%&&%%%%%%%%&%%%%&&&&&&& - 1 2.44
4 Orphan &&&&&%&&&&&&&&&&&&%&&&&&&&&&&&&&%%%%&&&&&&& - 1 2.44
4 Orphan &&%&&&&&&&&&&&&&&&&&&&&&&&%%%%%%%%%%&&&&&&& - 1 2.44
Subtotal 41 100.00
SIT, Spoligotype International Type according to the definitions in the SITVITWEB database (http://www.pasteur-guadeloupe.fr:8081/SITVIT_ONLINE/) accessed on April
2012.
1This strain was assigned to Lineage 3 (Delhi/CAS) based on alternative molecular markers, as previously published [31].
Lineage 1: Indo-Oceanic Lineage; Lineage 2: East-Asian Lineage (includes Beijing strains); Lineage 3: Delhi/CAS; Lineage 4: Euro-American Lineage.
doi:10.1371/journal.pone.0052297.t001
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frequent lineages were Lineage 3 (includes CAS/Delhi) with 106
isolates (40.6%) and Lineage 2 (East-Asian lineage, includes
Beijing genotype) with 84 isolates (32.2%). Forty one isolates
(15.7%) belonged to Lineage 4 (Euro-American Lineage), and
30 isolates (11.5%) to Lineage 1 (Indo-Oceanic Lineage).
Lineages 5 and 6 (M. africanum West African lineages) were
not found in our sample.
Based on spoligotyping, we detected 45 different spoligotypes
(SITs) corresponding to 225 M. tuberculosis isolates (Table 1). The
remaining 36 (13.8%) strains could not be assigned to any known
spoligotyping pattern in the SITVITWEB database, and were
therefore considered orphan spoligotypes. The spoligotyping
results showed that CAS family (90, 34.5%) and Beijing (84
isolates, 32.2%) were the predominant spoligotypes in our sample
(Table 1). Among the CAS family, the most prevalent spoligotype
was CAS1_DELHI (SIT 26) representing 52 (19.9%) isolates, and
almost all Beijing isolates (83 of 84 isolates belonging to Lineage 2)
showed the classical Beijing spoligotyping pattern. Of the 41
strains belonging to Lineage 4, we found spoligotypes that have
been reported before in India or Tibet (LAM9, H3, T2–T3, T1,
XI, H1, and H3) according to the SITVITWEB database. Among
the 30 (11.5%) Lineage 1 strains, only 18 (60.0%) matched the
SITs of the East African Indian (EAI) family. Only two SIT types
SIT 138 (EAI5; n = 10), and SIT 11 (EAI3_IND; n= 4) were
represented by more than one strain. However, SIT 1734
(EAI1_SOM) present as a single isolate in our dataset was not
reported before from the Indian sub-continent according to the
SITVITWEB database.
When comparing SNP typing with the spoligotyping results, we
found one case of ‘‘pseudo-Beijing’’ spoligotpype as previously
reported (Table 1) [31].
Drug Resistance
Overall, 50 (19.2%) M. tuberculosis isolates had any drug
resistance, and 16 (6.1%) were MDR as determined by DNA
sequencing of the main target regions (Table 2). Any drug
resistance was more frequently detected among previously treated
TB cases (29 cases, 30.0%) compared to new cases (21 cases,
12.8%, p= 0.001). Among the 16 MDR strains, 9 (56.3%) were
assigned to Lineage 2 (East-Asian Lineage), 6 (37.5%) to Lineage 3
(CAS/Delhi), and one (6.2%) to Lineage 4 (Euro-American
Lineage).
Association between M. tuberculosis Lineages and Patient
Characteristics
We observed that the proportion of female sex was different
across the four main M. tuberculosis lineages. Lineage 2 isolates were
more common among females (41.7%), compared to other
lineages (range 13.3% to 27.4%, overall p = 0.016, Table 2).
Moreover, any drug resistance was more frequently detected in
Lineage 2 isolates (31.0%) than in any other lineages (range 13.2%
to 14.6%, overall p = 0.011). Other patient characteristics such as
age, previous treatment history, or BCG vaccination were not
significantly associated with any of the four lineages (Table 2).
Because Lineage 2 (includes Beijing genotype) has been
previously associated with particular characteristics
Table 2. Associations of patient characteristics across the four main Mycobacterium tuberculosis lineages identified in Nepal.
Patient characteristics Total Lineage 1 Lineage 2 Lineage 3 Lineage 4 P value
n (%) (n=30) (n =84) (n=106) (n =41)
Age, median (IQR), years 31 (23–50) 42 (24–50) 30 (23.5–50.5) 30 (23–45) 38 (23–55) 0.50
Female sex 79 (30.3) 4 (13.3) 35 (41.7) 29 (27.4) 11 (26.8) 0.016
Previously treated 97 (37.2) 8 (26.7) 39 (46.4) 35 (33.0) 15 (36.6) 0.15
BCG vaccinated 110 (42.2) 13 (43.3) 31 (36.9) 46 (43.4) 20 (48.8) 0.62
Any resistance 50 (19.2) 4 (13.3) 26 (30.9) 14 (13.2) 6 (14.6) 0.011
MDR 16 (6.1) 0 9 (10.7) 6 (5.7) 1 (2.4) 0.14 1
BCG, Bacille Calmette Guerin; IQR, Interquartile range; MDR, Multidrug-resistant.
1Fisher’s exact test.
doi:10.1371/journal.pone.0052297.t002
Table 3. Multivariate associations between patient characteristics and Mycobacterium tuberculosis Lineage 2 (n = 84, includes the
Beijing genotype) compared to all other lineages (n = 177).
Patient characteristics Lineage 2 Unadjusted Adjusted
n (%) OR (95% CI) P value OR (95%CI) P value
Age, median (IQR), years 31 (23–50) 0.99 (0.98–1.01) 0.80 0.99 (0.98–1.01) 0.99
Female sex 35 (44.30) 2.15 (1.24–3.74) 0.006 2.58 (1.42–4.67) 0.002
Previously treated 39 (40.20) 1.77 (1.04–3.02) 0.034 1.68 (0.95–2.97) 0.074
BCG vaccinated 31 (28.18) 0.72 (0.42–1.23) 0.23 0.67 (0.37–1.20) 0.18
Any resistance 26 (52.00) 2.85 (1.51–5.37) 0.001 2.79 (1.43–5.45) 0.002
BCG, Bacille Calmette Guerin; IQR, Interquartile range; OR, Odds ratio; 95% CI, 95% confidence interval.
Model was adjusted for age, sex, previous TB treatment, BCG vaccination, and any resistance.
Lineage 1, 3 and 4 were used as the comparison group.
doi:10.1371/journal.pone.0052297.t003
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[17,19,21,47], and because Lineage 2 was the second most
common lineage in our sample, we tested whether these
characteristics were also associated with Lineage 2 in our setting
by comparing our Lineage 2 isolates to the other lineages
combined (Table 3). Logistic regression analyses showed that
Lineage 2 was associated with female sex (adjusted odds ratio
[aOR] 2.58; 95% confidence interval [95%CI] 1.42–4.67,
p = 0.002) and any drug resistance (aOR 2.79; 95%CI 1.43–
5.45, p = 0.002). A history of previous TB treatment tended to be
associated with Lineage 2 (aOR 1.68, 95% CI 0.95–2.97,
p = 0.074), while BCG vaccination status was not associated with
Lineage 2 (includes Beijing genotype) compared to other lineages
(aOR 0.67; 95%CI 0.37–1.20, p = 0.18).
Discussion
We analyzed 261 M. tuberculosis isolates from Nepal using SNP
typing and spoligotyping. We found that four main phylogenetic
lineages of M. tuberculosis were present in Nepal. Lineage 2 (East-
Asian Lineage, includes the Beijing genotype) and Lineage 3
(CAS/Delhi) were the most frequent, while Lineage 1 (Indo-
Oceanic Lineage) and Lineage 4 were less prevalent. Spoligotyp-
ing revealed a large genetic diversity with the predominant
spoligotyping families being Beijing and CAS/Delhi, and nearly
14% of spoligotyping patterns previously unreported.
Because Nepal is geographically located between India and
Tibet (China), we expected to observe similar M. tuberculosis
genotypes in Nepal as in these neighboring countries. Indeed,
Lineage 3 (corresponds to Delhi/CAS spoligotype), which was the
most common M. tuberculosis genotype in our sample, was
previously shown to be predominant in Northern India [48–50].
Similarly, Lineage 2 (includes Beijing), which was the second most
common genotype in our study has been reported as the most
frequent among TB cases from China (including Tibet) [22,51–
55]. The prevalence of the Beijing genotype of 32.2% in our study
is in the range of the prevalence reported from other Asian
countries, ranging from 17% in Malaysia to 72% in Japan [56].
Lineage 1 which is association with South-Indian region,
Bangladesh and the Philippines was also present in our study
sample [4].
We observed a discrepancy between SNP typing and spoligo-
typing results. Spoligotyping is based on the highly variable DR
locus, and convergent evolution may therefore lead to homoplasy
in spoligotyping patterns [5]. We found a strain with a Beijing
spoligotype, which was assigned to Lineage 3 (includes CAS
genotype) rather than to Lineage 2 (includes Beijing) based on
alternative molecular markers. We have previously published this
phenomenon as ‘‘Pseudo-Beijing’’ [31]. In Asian countries with a
high prevalence of Beijing spoligotypes, it is likely that this
phenomenon may be observed in other settings.
We found that Lineage 2 was associated with female sex, which
is in line with a previous study from Vietnam [57]. In contrast to
other studies [57,58] however, we found no evidence for an
association between Lineage 2 and age. Our observation may be
explained by bacterial factors or genetic host factors. Young and
middle-aged women may be more likely to progress from infection
to disease than men [59,60]. Alternatively, our results may be
influenced by recruitment of more young females than young
males into our study. Indeed, females were younger than males in
our study population. Overall, our study population showed a
male-to-female ratio of 2.3:1 which is similar to the global estimate
of 1.9:1 reported by WHO [2], and may reflect differences in
access to health care [61,62]. Furthermore, sex differences in TB
case notification rates among males and females have been noted
before in other settings [63,64].
Lineage 2 was also associated with any drug resistance. This is
consistent with previous studies from different settings [21,23].
The reasons for this association remain unknown [20], but the
strain genetic background of Beijing strains [65] and their
interactions with the human immune system may play a role
[21]. Alternatively, this association might reflect higher relapse
rates in patients infected with Beijing strains [66]. Indeed, in our
study, Lineage 2 included more patients that were previously
treated but this association was not statistically significant. Finally,
previous studies hypothesized that Beijing strain may escape the
protective immunity of BCG vaccination [21], but we found no
evidence for such an association between Lineage 2 and BCG
immunization. BCG immunization has been introduced in Nepal
more than 30 years ago, with an estimated immunization coverage
of 96% in 2009 [67]. However, larger studies may be required for
a more complete understanding of the association between
previous BCG vaccination and particular M. tuberculosis genotypes.
Our study has several limitations. First, the study was not
population-based as patients were recruited only at GENETUP
(Kathmandu), and patients diagnosed at other microscopy centers
during the study period could not be included. Second, patients
coming from more remote areas outside of Kathmandu might be
more likely to be referred as drug resistance suspects. Therefore,
this may have artificially increased the proportion of drug-resistant
strains in our sample. Third, although our study covered samples
from forty different districts of Nepal including those bordering
with India and Tibet, half of patients were from the Kathmandu
area. Therefore, the study results mainly reflect the genetic
diversity of the strains from the patients who visited GENETUP.
In conclusion, we found a high diversity of M. tuberculosis
genotypes in Nepal with representation of all four main M.
tuberculosis lineages, and showed that Lineage 2 (includes Beijing
genotype) was associated with female sex and any drug resistance.
This study fills the gap on the map of the genetic population
structure of M. tuberculosis in the Asian region by providing a first
insight into the phylogenetic lineages of M. tuberculosis circulating in
Nepal.
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